Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor–positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?Olga Nigro, Graziella Pinotti, Rossana Gueli et al.|Anti-Cancer Drugs|2020Cited by 4
CDK INHIBITORS PLUS LETROZOLE IN FIRST-LINE TREATMENT HR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER (ABC) WOMEN WITH VISCERAL DISEASE: TIME TO TURN PAGE?Elisa Gallerani, Graziella Pinotti, Olga Nigro et al.|The Breast|2019Cited by 0